Caris Life Sciences, Inc. Common Stock

Caris Life Sciences announced its common shares will begin trading on NYSE Texas on June 17, 2026, while continuing to list on Nasdaq under the ticker CAI. The company said the dual listing expands visibility among Texas and broader U.S. investors and reflects its strong connection to Texas, where it is headquartered and employs more than 450 people. Caris Life Sciences is a TechBio and precision medicine company that uses molecular profiling and AI to advance personalized oncology and chronic disease care. Separately, Wolfe Research analyst Mike Polark initiated coverage of CAI with a Peer Perform rating and no price target.

Caris Life Sciences, Inc. reported first-quarter 2026 revenue of $216.2 million, a 79% increase driven by a 61% rise in average selling prices and improving case volumes. Molecular profiling revenue grew 85%, gross margin expanded to 65% from 47%, and the company achieved positive Adjusted EBITDA and free cash flow. The precision oncology and AI-enabled diagnostics firm is transitioning into a multi-product platform with a pipeline that includes Caris Detect, ChromaSeq, MI Clarity, and minimal residual disease testing. Shares traded at $18.47 as of June 18th, with a forward price-to-earnings ratio of 46.95.

Caris Life Sciences announced that its Board of Directors authorized a program to repurchase up to $100 million of its outstanding common stock. The precision medicine and AI TechBio company plans to execute repurchases through open market purchases, private negotiations, or Rule 10b5-1 trading plans, adhering to federal securities laws including Rule 10b-18. Management will determine the timing and scale based on market conditions, stock price, and financial health, using existing cash reserves. The program has no expiration date and does not obligate the company to acquire a specific number of shares, and the Board may modify or suspend it at any time.